Half-year report on the liquidity contract between Safe Orthopaedics and Louis Capital Markets

Eragny-sur-Oise, France, July 30, 2020 – 18h00 CEST – Safe Orthopaedics (FR0013467123 - ALSAF), a company specializing in the design and marketing of ready-to-use technologies for spinal surgeries, delivering the safest treatment of spinal fractures urgently treated, is today releasing its half-year report on the liquidity contract signed with Louis Capital Markets on June 1, 2018.

The liquidity account had the following holdings as of June 30, 2020:

• 1 012 shares

• 364,57 euros

During the first half of 2020, the following have been negotiated:

PURCHASE	72 138 shares	9 771,00 euros	547 transactions
SALE	230 545 shares	9 894,38 euros	507 transactions

For the prior period (December 31, 2019), the corresponding figures were:

• 159 419 shares

• 1 623,33 euros

As of March 18, 2019 (implementation of the new liquidity contract), the followings were made available:

• 74 738 shares

• 7 561,33 euros

The detail of day-to-day activities is as follows:

	Purchase			Sale
ALSAF FP	Trading volume	Number of shares	Cash (EUR)	Trading volume	Number of shares	Cash (EUR)
Total	547	72 138	9 771,00	507	230 545	9 894,38
20200101	0	0	0,00	0	0	0,00
20200102	2	4 391	39,52	1	1	0,01
20200103	2	3 891	32,69	1	1	0,01
20200106	1	1	0,01	1	1	0,01
20200107	1	1	0,01	11	38 511	401,57
20200108	10	37 031	437,66	2	2 851	38,77
20200109	2	2 981	32,79	2	4 871	58,45
20200110	1	1	0,01	2	4 821	57,85
20200113	1	1	0,01	11	35 411	478,84
20200114	1	1	0,02	11	27 411	434,21
20200115	5	15 491	240,57	7	15 771	280,75
20200116	1	1	0,02	2	1 961	34,51
20200117	1	610	1 604,30	1	91 599	1 602,98
20200120	9	172	391,58	4	33	80,45
20200121	11	183	391,24	1	1	2,30
20200122	6	85	159,97	2	21	41,57
20200123	8	118	203,93	2	31	57,44
20200124	1	1	1,80	11	230	418,10
20200127	6	94	169,59	2	21	39,89
20200128	4	58	98,89	5	88	161,02
20200129	6	96	160,69	4	71	125,62
20200130	6	96	155,51	2	21	35,70
20200131	4	58	93,22	5	88	147,89
20200203	5	76	122,44	2	21	35,14
20200204	1	1	1,64	4	81	132,76
20200205	4	60	93,19	3	41	65,84
20200206	5	78	122,04	2	21	34,23
20200207	3	38	58,66	4	81	131,22
20200210	4	60	90,85	2	21	32,65
20200211	5	78	115,20	1	1	1,50
20200212	4	61	87,87	9	201	309,91
20200213	6	111	168,65	2	21	33,60
20200214	5	81	119,80	1	1	1,50
20200217	6	101	145,54	1	1	1,50
20200218	6	99	134,36	2	31	44,33
20200219	4	59	79,65	5	111	158,92
20200220	5	80	108,29	5	111	163,17
20200221	5	80	105,69	1	1	1,36
20200224	11	215	250,70	1	1	1,28
20200225	5	159	183,77	5	141	169,99
20200226	5	70	80,48	2	41	49,20
20200227	5	203	226,77	3	71	83,64
20200228	6	72	78,59	1	1	1,11
20200302	4	49	49,70	7	221	243,52
20200303	3	24	24,32	4	109	114,45
20200304	4	51	50,72	1	1	1,03
20200305	8	137	124,96	1	1	0,96
20200306	6	79	66,02	1	1	0,87
20200309	1	1	0,78	1	1	0,78
20200310	5	76	53,94	2	51	37,59
20200311	3	170	119,98	8	531	391,42
20200312	8	144	98,22	6	157	125,57
20200313	5	86	55,55	2	31	20,97
20200316	10	236	141,21	5	90	60,78
20200317	4	44	24,96	6	94	57,73
20200318	9	101	55,75	5	74	49,72
20200319	7	178	106,56	9	208	137,28
20200320	6	50	29,00	4	371	229,34
20200323	4	34	20,40	4	50	31,45
20200324	1	1	0,66	10	154	101,02
20200325	4	50	30,80	2	2	1,29
20200326	3	33	19,49	4	48	30,91
20200327	3	33	19,28	3	20	12,20
20200330	2	21	12,20	4	48	28,93
20200331	4	51	29,24	2	23	13,49
20200401	1	1	0,59	11	154	94,19
20200402	11	106	88,69	3	37	34,86
20200403	5	60	42,09	3	45	33,89
20200406	3	24	16,79	15	309	230,75
20200407	4	36	25,79	3	29	21,62
20200408	4	36	25,19	4	36	27,00
20200409	3	31	21,01	4	36	25,92
20200410	0	0	0,00	0	0	0,00
20200413	0	0	0,00	0	0	0,00
20200414	4	44	29,73	1	1	0,70
20200415	3	29	19,54	11	115	84,96
20200416	1	1	0,72	11	106	77,19
20200417	6	64	50,96	10	84	75,14
20200420	4	38	28,74	1	1	0,77
20200421	4	39	27,59	1	1	0,73
20200422	2	21	14,35	4	31	21,95
20200423	3	34	23,83	2	12	8,71
20200424	2	18	12,35	3	27	19,10
20200427	4	39	26,45	1	1	0,68
20200428	3	31	21,03	4	33	23,33
20200429	3	31	21,35	4	33	23,78
20200430	4	48	33,01	1	1	0,71
20200501	0	0	0,00	0	0	0,00
20200504	6	83	56,02	1	1	0,68
20200505	3	28	18,96	2	17	12,03
20200506	4	53	35,48	1	1	0,69
20200507	1	1	0,68	11	131	96,28
20200508	4	31	21,37	3	23	16,51
20200511	4	32	21,69	2	16	11,20
20200512	9	108	68,11	1	1	0,67
20200513	3	25	15,43	11	130	89,35
20200514	9	115	67,75	4	31	20,65
20200515	3	27	15,52	3	27	16,13
20200518	4	35	19,93	2	18	10,61
20200519	4	33	19,21	1	1	0,60
20200520	4	32	18,29	1	1	0,58
20200521	4	32	18,22	2	20	11,77
20200522	4	32	17,97	2	20	11,62
20200525	3	25	13,82	4	39	22,52
20200526	1	1	0,57	6	68	40,60
20200527	4	32	19,19	3	28	17,57
20200528	4	30	17,98	2	15	9,33
20200529	4	32	19,21	1	1	0,62
20200601	1	1	0,61	10	128	81,10
20200602	1	1	0,67	9	145	101,32
20200603	11	257	165,81	4	53	37,10
20200604	5	91	55,03	4	57	35,50
20200605	5	121	71,17	2	11	6,69
20200608	5	81	46,77	2	31	18,38
20200609	1	1	0,60	10	217	134,12
20200610	5	101	60,08	6	97	60,36
20200611	5	111	65,15	4	56	34,13
20200612	2	31	17,68	8	139	82,75
20200615	1	1	0,57	4	56	32,60
20200616	4	91	52,07	2	21	12,31
20200617	4	91	51,66	10	161	99,46
20200618	9	203	110,33	1	1	0,57
20200619	6	137	73,08	1	1	0,54
20200622	5	81	42,07	5	111	60,02
20200623	5	87	44,50	3	33	17,59
20200624	1	1	0,54	9	199	108,77
20200625	5	81	43,48	4	58	32,42
20200626	8	122	63,09	5	78	42,45
20200629	4	59	29,88	6	109	57,63
20200630	5	77	39,07	1	1	0,51

Next financial release:

First semester 2020 results, September 28th, 2020 (post-market)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company, a pioneer of the design and marketing of innovative ready-to-use technologies (single-use implants and instruments) for spinal diseases, delivering the safest treatment of spinal fractures. The technologies include sterile implants and ready-to-use instruments available to the surgeon at any time and anywhere, enabling minimally invasive approaches, reducing the risks of cross contamination and infection in the interest of the patient. Protected by 17 patent families, the SteriSpine^TM Kits are CE marked, FDA and CFDA approved. Safe Orthopaedics, has its headquarter close to Paris (95610 Eragny-Sur-Oise - France) and has created a subsidiary in the UK, Germany and in the US, employing around 50 employees for a total sales of 4.7M€ in 2019. For more information : www.SafeOrthopaedics.com

Contacts

Safe Orthopaedics
François-Henri Reynaud
Chief Financial Officer
Tél. : +33 (0)1 34 21 50 00
investors@safeorthopaedics.com

Press Relations
Ulysse Communication
Bruno Arabian / +33 (0)6 87 88 47 26 / barabian@ulysse-communication.com
Nicolas Daniels / +33 (0)6 63 66 59 22 / ndaniels@ulysse-communication.com

Attachment

• CP EN 30-07-20